Arca
Skip to content
Tools
Tools

Type 2 diabetes

Drug research and approvals for type 2 diabetes: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 884 studies of type 2 diabetes are recruiting on ClinicalTrials.gov, Health Canada has authorized 148 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 41 authorised medicines for it.

  • Recruiting worldwide: 884
  • Trials authorized in Canada: 148
  • FDA orphan approvals: 1
  • EU medicines: 41

Recruiting now

Newest posted first, of 884 recruiting on ClinicalTrials.gov ↗

How its trials ended

8,392 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 2,232 whose ending is known, 68% met their primary endpoint, 4% missed it and 28% stopped early.

  • Completed, result not reported4,05148%
  • Met its primary endpoint1,52118%
  • Ongoing1,13714%
  • Status unknown97212%
  • Stopped: other or unclear3544%
  • Stopped: enrollment or feasibility1141%
  • Missed its primary endpoint921%
  • Stopped: sponsor or business decision881%
  • Stopped: lack of efficacy30<1%
  • Stopped: funding20<1%
  • Stopped: safety13<1%

Trials authorized in Canada

The 10 newest of 148; search them all in Canada trials
Aug 21, 2026Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at higher dose levels in participants with type 2 diabetes…Zenagamtide / OzempicNovo NordiskOngoing
Aug 20, 2026A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of once weekly petrelintide vs. placebo in…Petrelintide (RO7895515)RochePending
Aug 18, 2026A phase 3, randomized, open-label trial comparing the efficacy and safety of maridebart cafraglutide once monthly versus semaglutide once weekly as add-on…Maridebart cafraglutide (amg 133)AmgenOngoing
Aug 18, 2026A phase 3, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of maridebart cafraglutide versus placebo in participants with…Maridebart cafraglutide (amg 133)AmgenPending
Aug 11, 2026Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased…ZenagamtideNovo NordiskOngoing
Aug 5, 2026A phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of once-weekly eloralintide in adult participants with…Eloralintide (LY3841136)Eli LillyPending
Jul 23, 2026A phase III randomised, double-blind, placebo-controlled multicentre trial to evaluate the efficacy and safety of AZD6234 as an adjunct to incretin-based…Lenbelintide (AZD6234)AstraZeneca PharmaceuticalsOngoing
Jul 23, 2026A phase III randomized, double-blind, placebo-controlled multicentre trial to evaluate the efficacy and safety of AZD6234 in participants with type 2 diabetes…Lenbelintide (AZD6234)AstraZeneca PharmaceuticalsOngoing
Jun 24, 2026A phase 3, randomized, double-blind extension trial to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants…Maridebart cafraglutide (amg 133)AmgenOngoing
Jun 11, 2026A phase III, randomised, double-blind, parallel-group, 56-week study, evaluating the efficacy and safety of survodutide (BI456906), compared with placebo, in…Survodutide (bi 456906)Boehringer Ingelheim (Canada) Ltd LteeOngoing

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Feb 17, 2012KorlymFor the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2…Corcept Therapeutics, Inc.Approved

Medicines authorised in the EU

Newest first; 15 of 41
Jul 15, 2026Liraglutide STADALiraglutideSTADA Arzneimittel AGEMA ↗
Nov 24, 2025KyinsuInsulin icodec; semaglutideNovo Nordisk A/SEMA ↗
Mar 31, 2023Sitagliptin / Metformin hydrochloride SunSitagliptin; metformin hydrochloride · genericSun Pharmaceutical Industries Europe B.V.EMA ↗
Mar 24, 2023Dapagliflozin ViatrisDapagliflozin · genericViatris LimitedEMA ↗
Sep 15, 2022MounjaroTirzepatideEli Lilly Nederland B.V.EMA ↗
Apr 25, 2022Sitagliptin AccordSitagliptin · genericAccord Healthcare S.L.U.EMA ↗
Mar 24, 2022Vildagliptin / Metformin hydrochloride AccordVildagliptin; metformin hydrochloride · genericAccord Healthcare S.L.U.EMA ↗
Feb 16, 2022Sitagliptin / Metformin hydrochloride MylanSitagliptin hydrochloride monohydrate; metformin hydrochloride · genericMylan Pharmaceuticals LimitedEMA ↗
Feb 16, 2022KerendiaFinerenoneBayer AGEMA ↗
Dec 9, 2021Sitagliptin SUNSitagliptin fumarate · genericSun Pharmaceutical Industries Europe B.V.EMA ↗
Apr 3, 2020RybelsusSemaglutideNovo Nordisk A/SEMA ↗
Mar 23, 2018SteglujanErtugliflozin; sitagliptinMerck Sharp & Dohme B.V.EMA ↗
Mar 23, 2018SeglurometErtugliflozin; metformin hydrochlorideMerck Sharp & Dohme B.V.EMA ↗
Mar 21, 2018SteglatroErtugliflozinMerck Sharp & Dohme B.V.EMA ↗
Feb 8, 2018OzempicSemaglutideNovo Nordisk A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.